These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

514 related items for PubMed ID: 8100611

  • 1. Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter. The European-Australian Collaborative Group.
    Cooper DA, Gatell JM, Kroon S, Clumeck N, Millard J, Goebel FD, Bruun JN, Stingl G, Melville RL, González-Lahoz J.
    N Engl J Med; 1993 Jul 29; 329(5):297-303. PubMed ID: 8100611
    [Abstract] [Full Text] [Related]

  • 2. Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases.
    Volberding PA, Lagakos SW, Koch MA, Pettinelli C, Myers MW, Booth DK, Balfour HH, Reichman RC, Bartlett JA, Hirsch MS.
    N Engl J Med; 1990 Apr 05; 322(14):941-9. PubMed ID: 1969115
    [Abstract] [Full Text] [Related]

  • 3. A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. AIDS Clinical Trials Group.
    Volberding PA, Lagakos SW, Grimes JM, Stein DS, Rooney J, Meng TC, Fischl MA, Collier AC, Phair JP, Hirsch MS.
    N Engl J Med; 1995 Aug 17; 333(7):401-7. PubMed ID: 7616988
    [Abstract] [Full Text] [Related]

  • 4. A controlled trial of zidovudine in primary human immunodeficiency virus infection.
    Kinloch-De Loës S, Hirschel BJ, Hoen B, Cooper DA, Tindall B, Carr A, Saurat JH, Clumeck N, Lazzarin A, Mathiesen L.
    N Engl J Med; 1995 Aug 17; 333(7):408-13. PubMed ID: 7616989
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.
    Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, Eron JJ, Feinberg JE, Balfour HH, Deyton LR, Chodakewitz JA, Fischl MA.
    N Engl J Med; 1997 Sep 11; 337(11):725-33. PubMed ID: 9287227
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Evaluation of the quality of life associated with zidovudine treatment in asymptomatic human immunodeficiency virus infection. The AIDS Clinical Trials Group.
    Lenderking WR, Gelber RD, Cotton DJ, Cole BF, Goldhirsch A, Volberding PA, Testa MA.
    N Engl J Med; 1994 Mar 17; 330(11):738-43. PubMed ID: 7906386
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS.
    O'Brien WA, Hartigan PM, Martin D, Esinhart J, Hill A, Benoit S, Rubin M, Simberkoff MS, Hamilton JD.
    N Engl J Med; 1996 Feb 15; 334(7):426-31. PubMed ID: 8552144
    [Abstract] [Full Text] [Related]

  • 12. A pilot study of low-dose zidovudine in human immunodeficiency virus infection.
    Collier AC, Bozzette S, Coombs RW, Causey DM, Schoenfeld DA, Spector SA, Pettinelli CB, Davies G, Richman DD, Leedom JM.
    N Engl J Med; 1990 Oct 11; 323(15):1015-21. PubMed ID: 1977080
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Zidovudine, didanosine, or both as the initial treatment for symptomatic HIV-infected children. AIDS Clinical Trials Group (ACTG) Study 152 Team.
    Englund JA, Baker CJ, Raskino C, McKinney RE, Petrie B, Fowler MG, Pearson D, Gershon A, McSherry GD, Abrams EJ, Schliozberg J, Sullivan JL.
    N Engl J Med; 1997 Jun 12; 336(24):1704-12. PubMed ID: 9182213
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Zidovudine monotherapy versus zidovudine plus zalcitabine combination therapy in HIV-positive persons with CD4 cell counts 300-500 cells/mm3: a double-blind controlled trial. The M50003 Study Group Coordinating and Writing Committee.
    Moyle GJ, Bouza E, Antunes F, Smith D, Harris R, Warburg M, Walker M.
    Antivir Ther; 1997 Dec 12; 2(4):229-36. PubMed ID: 11327442
    [Abstract] [Full Text] [Related]

  • 19. A short-term clinical evaluation of L-697,661, a non-nucleoside inhibitor of HIV-1 reverse transcriptase. L-697,661 Working Group.
    Saag MS, Emini EA, Laskin OL, Douglas J, Lapidus WI, Schleif WA, Whitley RJ, Hildebrand C, Byrnes VW, Kappes JC.
    N Engl J Med; 1993 Oct 07; 329(15):1065-72. PubMed ID: 7690462
    [Abstract] [Full Text] [Related]

  • 20. Zidovudine twice daily in asymptomatic subjects with HIV infection and a high risk of progression to AIDS: a randomized, double-blind placebo-controlled study. The European-Australian Collaborative Group (Study 017).
    Mulder JW, Cooper DA, Mathiesen L, Sandström E, Clumeck N, Gatell JM, French M, Donovan B, Gray F, Yeo JM.
    AIDS; 1994 Mar 07; 8(3):313-21. PubMed ID: 7913326
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.